2-((2-((4-(4-((4-(tert-butyl)phenyl)amino)phenoxy)-6-methoxyquinolin-7-yl)oxy)ethyl)amino)ethanol | 516523-31-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-((2-((4-(4-((4-(tert-butyl)phenyl)amino)phenoxy)-6-methoxyquinolin-7-yl)oxy)ethyl)amino)ethanol
• 英文别名: Ki23057；2-({2-[(4-{4-[4-(tert-butyl)anilino]phenoxy}-6-methoxy-7-quinolyl)oxy]ethyl}amino)-1-ethanol；2-[2-[4-[4-(4-tert-butylanilino)phenoxy]-6-methoxyquinolin-7-yl]oxyethylamino]ethanol
• CAS: 516523-31-2
• 化学式: C₃₀H₃₅N₃O₄
• 分子量: 501.626
• InChiKey: VQCDZFWRGXFUMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.9
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  [4-(7-Benzyloxy-6-methoxy-4-quinolyloxy)phenyl](4-tert-butylphenyl)amine 在 甲烷磺酸 、 potassium carbonate 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-((2-((4-(4-((4-(tert-butyl)phenyl)amino)phenoxy)-6-methoxyquinolin-7-yl)oxy)ethyl)amino)ethanol
  参考文献：
  名称：

  Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors

  摘要：

  (6,7-二取代喹啉-4-基氧苯基)(4-取代苯基)胺衍生物通过在人瘢痕胃癌细胞系OCUM-2MD3中进行成纤维细胞生长因子受体2（FGF-R2）的细胞自体磷酸化试验而被合成和评估。我们还进行了代谢稳定性研究，结果显示喹啉环7位的取代基会影响其生物稳定性。在本研究中，我们显著改善了双苯胺衍生物的溶解性和代谢稳定性。最具潜力的化合物15e在口服给药时表现出肿瘤体积的显著减少。 ©2003 Elsevier Ltd. 保留所有权利。

  DOI：

  10.1016/j.bmcl.2003.12.019

文献信息

• METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR
  申请人：Uenaka Toshimitsu

  公开号：US20100092490A1

  公开（公告）日：2010-04-15

  The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.

  本发明提供了一种预测抗血管生成抑制剂的抗肿瘤效果的方法。通过评估肿瘤细胞对表皮生长因子（EGF）增殖和/或存活的依赖性，并将其作为指标，可以预测抗血管生成抑制剂的抗肿瘤效果。由于抗血管生成抑制剂的抗肿瘤效果与肿瘤细胞对EGF增殖和/或存活的依赖性相关，因此当与具有EGF抑制活性的物质结合时，抗血管生成抑制剂能够产生出色的抗肿瘤效果。
• Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
  申请人：Miwa Atsushi

  公开号：US20050049264A1

  公开（公告）日：2005-03-03

  An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR 10 , CR 11 R 2 , carbonyl, O, S(═O)m, wherein m is 0 to 2, or urea; R 1 to R 3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R 4 represents H; R 5 to R 8 each independently represent H, halogen, alkyl, or alkoxy; and R 9 represents an optionally substituted carbocyclic or heterocyclic group.

  本发明的目标是提供新型化合物，其具有对FGF受体家族自磷酸化的抑制活性，并在口服或静脉注射时能够抑制癌细胞的生长。本发明的化合物由公式（I）或其药学上可接受的盐或溶剂表示：其中X代表CH或N; Z代表O或S; Q代表NR10，CR11R2，羰基，O，S（═O）m，其中m为0到2，或脲基; R1至R3各自独立地表示H、OH、卤素、硝基、氨基、烷基、烷氧基或其类似物，其中烷基和烷氧基基团可选择性地被取代; R4表示H; R5至R8各自独立地表示H、卤素、烷基或烷氧基; R9表示一个可选择性取代的碳环或杂环基团。
• QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1447405A1

  公开（公告）日：2004-08-18

  An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents 0 or S; Q represents NR10, CR11R12, carbonyl, O, S(=O)m, wherein m is 0 to 2, or urea; R1 to R3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R4 represents H; R5 to R8 each independently represent H, halogen, alkyl, or alkoxy; and R9 represents an optionally substituted carbocyclic or heterocyclic group.

  本发明的目的是提供对 FGF 受体家族的自身磷酸化具有抑制活性的新型化合物，口服或静脉注射后可抑制癌细胞的生长。本发明的化合物由式（I）或其药学上可接受的盐或溶液表示： 其中 X 代表 CH 或 N；Z 代表 0 或 S；Q 代表 NR10、CR11R12、羰基、O、S(＝O)m（其中 m 为 0 至 2）或脲；R1 至 R3 各自独立地代表 H、OH、卤素、硝基、氨基、烷基、烷氧基或类似基团，其中烷基和烷氧基是任选取代的；R4 代表 H；R5 至 R8 各自独立地代表 H、卤素、烷基或烷氧基；R9 代表任选取代的碳环或杂环基团。
• METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP1925941A1

  公开（公告）日：2008-05-28

  It is an object of the present invention to find out a method of predicting the antitumor effect of an angiogenesis inhibitor. According to the present invention, it is possible to predict the antitumor effect of an angiogenesis inhibitor by determining the number of those blood vessels which are covered with pericytes in a tumor and using the resultant number as an indicator.

  本发明的目的是找到一种预测血管生成抑制剂抗肿瘤效果的方法。根据本发明，可以通过确定肿瘤中被周细胞覆盖的血管的数量，并以该数量作为指标，来预测血管生成抑制剂的抗肿瘤效果。
• Anti-tumour pharmaceutical composition with angiogenesis inhibitors
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2281901A2

  公开（公告）日：2011-02-09

  The present invention provides a pharmaceutical composition comprising a VEGF receptor kinase inhibitor in combination with a substance having EGF inhibitory activity. The pharmaceutical composition can be used in a method of treating cancer. The invention also provides kits containing a combination of a preparation comprising a VEGF receptor kinase inhibitor and a preparation comprising a substance having EGF inhibitory activity.

  本发明提供了一种药物组合物，它包含一种血管内皮生长因子受体激酶抑制剂与一种具有表皮生长因子抑制活性的物质。该药物组合物可用于治疗癌症的方法中。本发明还提供了包含由血管内皮生长因子受体激酶抑制剂组成的制剂和由具有 EGF 抑制活性的物质组成的制剂组合的试剂盒。